These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Antiproteinuric effect of cyclosporine A in passive antiglomerular basement membrane nephritis in the mouse. Schrijver G; Wetzels JF; Robben JC; Assmann KJ; Koene RA; Berden JH Transplant Proc; 1988 Jun; 20(3 Suppl 4):304-8. PubMed ID: 3381288 [No Abstract] [Full Text] [Related]
28. Cyclosporine trials in diabetes: updated results of the French experience. Assan R; Feutren G; Sirmai J Transplant Proc; 1988 Jun; 20(3 Suppl 4):178-83. PubMed ID: 3289203 [No Abstract] [Full Text] [Related]
29. The place of cyclosporine A in the treatment of connective tissue diseases. Miescher PA; Favre H; Mihatsch MJ; Chatelanat F; Huang YP; Zubler R Transplant Proc; 1988 Jun; 20(3 Suppl 4):224-37. PubMed ID: 3381275 [No Abstract] [Full Text] [Related]
30. Comparison of the efficacy of unilateral, bilateral, and oral cyclosporine in experimental immunogenic uveitis in rabbits. Kaswan RL; Kaplan HJ Transplant Proc; 1988 Jun; 20(3 Suppl 4):149-57. PubMed ID: 3289202 [No Abstract] [Full Text] [Related]
31. [Use of cyclosporin A in autoimmune diseases]. Schädelin J; Von Graffenried B Presse Med; 1987 Mar; 16(11):542-3. PubMed ID: 2951703 [No Abstract] [Full Text] [Related]
32. [Autoimmune skin diseases and cyclosporin A]. Alijotas Reig J; Pedragosa Jové R Med Clin (Barc); 1989 May; 92(20):772-5. PubMed ID: 2677537 [No Abstract] [Full Text] [Related]
34. Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases. Skundric DS Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):3. PubMed ID: 29474167 [No Abstract] [Full Text] [Related]
35. Results of a one-year open trial of cyclosporine in ten patients with severe myasthenia gravis. Goulon M; Elkharrat D; Lokiec F; Gajdos P Transplant Proc; 1988 Jun; 20(3 Suppl 4):211-7. PubMed ID: 3260050 [No Abstract] [Full Text] [Related]
36. Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: II. Reduction of glomerulonephritis. Gunn HC; Ryffel B Clin Exp Immunol; 1986 May; 64(2):234-42. PubMed ID: 3742874 [TBL] [Abstract][Full Text] [Related]
37. New cyclosporine derivative SDZ IMM 125: in vitro and in vivo pharmacologic effects and toxicologic evaluation. Hiestand PC; Gräber M; Hurtenbach U; Herrmann P; Cammisuli S; Richardson BP; Eberle MK; Donatsch P; Ryffel B; Borel JF Transplant Proc; 1993 Feb; 25(1 Pt 1):691-2. PubMed ID: 8438439 [No Abstract] [Full Text] [Related]
38. Ciclosporin therapy of autoimmune diseases. Cruse JM; Lewis RE Concepts Immunopathol; 1989; 7():1-19. PubMed ID: 2676175 [No Abstract] [Full Text] [Related]